Phaco vs. Phaco-ELT vs. Phaco-Trabectome 12m
Launched by UNIVERSITY OF ZURICH · Sep 1, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
Glaucoma is one of the most common reasons for blindness. Usually an elevated drain resistance is the reason, while aqueous humor production is normal. Medical reduction of intraocular pressure (IOP) is first line therapy in most cases. The gold standard of surgical treatment still is trabeculectomy (TE) but TE has a lot of drawbacks. In particular when glaucoma and cataract coexists, the investigators therefore prefer the combined procedure cataract extraction plus excimer laser trabeculotomy (ELT) or plus Trabectome. Indication is cataract and a moderate elevated IOP without medical thera...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • All patients, which had Phaco, Phako/ELT, or Phaco-Trabectome from 01/2008 until 12/2011, where screened 12 month after surgery
- Exclusion criteria:
- • IOP \>35 mmHg
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
01 Studienregister MasterAdmins
Study Director
UniversitaetsSpital Zuerich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials